We found that an estradiol-challenge test that monitors an increase in tumor PgR by FFNP-PET can rapidly and accurately predict response or lack thereof to subsequent ET in patients with advanced ER+ breast cancer. This evidence concerns the gene ESR1 and neoplasm.